Luna Diabetes Raises Series A Financing to Advance its Automated Insulin Delivery Solution For Insulin Pen Users

Luna Diabetes完成A轮融资，以推进其为胰岛素笔用户提供的自动胰岛素输送解决方案。

SAN DIEGO, Calif., August 18, 2025-- Luna Health Inc., a medical device company pioneering a first-of-its-kind method of insulin delivery for insulin pen users, today announced the closing of its $23.6M Series A financing led by Vensana Capital, with participation from the Swiss Diabetes Venture Fund, Ascensia Diabetes Care, Winklevoss Capital, and other prominent investors with deep expertise in diabetes technology and value creation.

圣地亚哥，加利福尼亚州，2025年8月18日——Luna Health Inc.是一家医疗设备公司，为胰岛素笔用户开创了一种全新的胰岛素输送方法。该公司今天宣布完成了由Vensana Capital领投的2360万美元A轮融资，瑞士糖尿病风险投资基金、Ascensia Diabetes Care、Winklevoss Capital以及其他在糖尿病技术和价值创造方面拥有深厚专业知识的知名投资者也参与了本轮融资。

The funding will accelerate development of Luna, the world's smallest insulin patch pump paired with the firm's fully closed-loop insulin dosing algorithm, created to serve the vast majority of people with Type 2 Diabetes (T2D) and Type 1 Diabetes (T1D) who rely on insulin pens..

这笔资金将加速世界上最小的胰岛素贴片泵Luna的开发，该产品与公司完全闭环的胰岛素剂量算法相结合，旨在服务于依赖胰岛素笔的大多数2型糖尿病（T2D）和1型糖尿病（T1D）患者。

Luna's first-in-class, low-profile, iCGM-compatible, low-cost patch pump delivers automated doses of rapid-acting insulin during sleep, when over 80% of the glucose improvement from traditional pump-based automated insulin delivery happens, without requiring people with diabetes to make the leap to full-time pump therapy.

Luna首创的低轮廓、兼容iCGM的低成本贴片泵，在睡眠期间自动输送速效胰岛素，此时传统基于泵的自动胰岛素输送所实现的超过80%的血糖改善发生，且无需糖尿病患者转为全职泵治疗。

By focusing on where automation has the greatest impact on glucose control, Luna dramatically reduces complexity, lowers costs, and reduces barriers to adoption, thereby making automated insulin delivery accessible to millions of people worldwide who are either unwilling or unable to wear a traditional pump 24/7..

通过专注于自动化对血糖控制影响最大的方面，Luna极大地降低了复杂性、减少了成本并消除了采用的障碍，从而使全球数百万不愿意或无法24/7佩戴传统泵的人能够使用自动胰岛素输送。

'We are incredibly excited and fortunate to partner with Vensana Capital to accelerate bringing to market our products that solve the single largest problem in all of diabetes - nighttime glucose control for pen users,' added Jon Brilliant, co-founder and CFO of Luna. 'Vensana's track record and leadership in the medical device ecosystem further bolsters the world-class team of employees and advisors that we have assembled to tackle this problem.'.

“我们非常兴奋并感到幸运能与Vensana资本合作，加速将我们的产品推向市场，解决糖尿病领域最大的问题——注射笔用户的夜间血糖控制，”Luna的联合创始人兼首席财务官Jon Brilliant补充道。“Vensana在医疗器械生态系统中的业绩和领导地位进一步增强了我们为解决这一问题所组建的世界级员工和顾问团队。”

'Luna is solving a challenge the diabetes field has struggled with for decades-bringing the benefits of automation to injection users,' said Justin Klein, MD, JD, co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. 'Luna's platform has the potential to fundamentally expand the reach of automated insulin delivery and drive measurable improvements in outcomes for people with both Type 1 and Type 2 diabetes.'.

“Luna正在解决糖尿病领域几十年来一直面临的一个挑战——将自动化的优势带给注射使用者，”专注于医疗技术创新的风险投资和成长股权公司Vensana Capital的联合创始人兼管理合伙人Justin Klein（医学博士、法学博士）表示，“Luna的平台有潜力从根本上扩大自动胰岛素输送的覆盖范围，并为1型和2型糖尿病患者带来可衡量的结果改善。”

The company will use the Series A funding to advance regulatory submissions, conduct clinical studies, build manufacturing capacity, and expand clinical and market access programs -- all to make automated insulin delivery much more accessible to people with diabetes.

公司将利用A轮融资来推进监管提交、开展临床研究、建立生产能力，并扩展临床和市场准入计划——所有这些都是为了使自动胰岛素输送对糖尿病患者更加可及。

About Luna Health Inc.

关于Luna Health Inc.

Luna Health Inc.'s mission is to empower millions using insulin pens to manage their diabetes effortlessly while they sleep. Its flagship product, Luna, combines the world's smallest insulin patch pump with a fully closed-loop algorithm to automate insulin delivery during sleep and support users across the day, without requiring a switch to a full-time insulin pump.

Luna Health Inc. 的使命是让数百万使用胰岛素笔的用户在睡眠中轻松管理糖尿病。其旗舰产品 Luna 将全球最小的胰岛素贴片泵与完全闭环算法相结合，在睡眠期间自动输送胰岛素，并在全天为用户提供支持，且无需切换到全职胰岛素泵。

Headquartered in San Diego, California, Luna develops solutions that are simple to start, easy to live with, and available through insurance. Learn more at lunadiabetes.com..

总部位于加利福尼亚州圣地亚哥的Luna开发的解决方案简单易用、易于接受，并且可以通过保险获得。欲了解更多信息，请访问lunadiabetes.com。

About Vensana Capital

关于Vensana资本

Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Founded in 2019, Vensana has approximately $1 billion in capital under management and is actively investing in development and commercial-stage companies across the medtech sector, including medical devices, data science-oriented solutions, life science tools & diagnostics, and tech-enabled services.

Vensana Capital 是一家风险投资和成长股权公司，致力于与那些希望通过突破性医疗技术创新来变革医疗保健的企业家合作。公司成立于 2019 年，管理着约 10 亿美元的资本，并积极投资于医疗技术领域的开发和商业化阶段公司，包括医疗器械、数据科学导向型解决方案、生命科学工具与诊断以及技术赋能服务。

Vensana's investment team has a history of successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical.

Vensana 的投资团队有着与行业领先企业背后的企业家成功合作的历史，这些公司包括 Artelon、Cameron Health、CardiAQ、Cartiva、CV Ingenuity、CVRx、Epix Therapeutics、Inari Medical、Intact Vascular、Lutonix、Neuwave Medical、Personal Genome Diagnostics、Relievant Medsystems、Sequent Medical、Topera、Ulthera、Veran Medical Technologies、Vertiflex 和 Vesper Medical。

Learn more at www.vensanacap.com..

欲了解更多信息，请访问 www.vensanacap.com。

Contact:

联系：

Media Contact

媒体联系人

Luna Health Inc.

月光健康公司

press@lunadiabetes.com

press@lunadiabetes.com